Takuyo Kanayama
Takuyo Kanayama has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Hajime Hosoi
Department of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto, Japan
4 shared publicationsHiroshi Komatsu
Department of Pediatrics National Hospital Organization Maizuru Medical Center Maizuru Japan
3 shared publicationsShinya Osone
Department of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto, Japan
3 shared publicationsToshihiko Imamura
Department of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto, Japan
3 shared publications- Toshihiko Imamura
Department of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto, Japan
3 shared publications - Hajime Hosoi
Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan
2 shared publications
Latest Publications
- 1 January 2024
- Published by Wiley in Pediatrics International
- Vol. 66 (1) , e15753
Oxygenation saturation index in neonatal hypoxemic respiratory failure
Background: This study aimed to assess the validity of the oxygenation saturation index (OSI) and the ratio of oxygen saturation to the fraction of inspired oxygen (F I O 2 ) (S/F ratio) with percutaneous oxygen saturation (OSI SpO2 and the S p /F ratio) and to evaluate the correlation between these values and the oxygen index (OI). It also determined their cut‐off values for predicting OI in accordance with neonatal hypoxic respiratory failure severity. Methods: We reviewed the data of 77 neonates (gestational age 31.7 ± 6.1 weeks; birthweight, 1768 ± 983 g) requiring invasive mechanical ventilation between 2013 and 2020, 1233 arterial blood gas samples in total. We calculated the OI, OSI SpO2 , OSI with arterial oxygen saturation (SaO 2 ) (OSI SaO2 ), S p /F ratio, and the ratio of SaO 2 to F I O 2 (S a /F ratio). Results: The regression and Bland–Altman analysis showed good agreement between OSI SpO2 or the S p /F ratio and OSI SaO2 or the S a /F ratio. Although a significant positive correlation was found between OSI SpO2 and OI, OSI SpO2 was overestimated in SpO 2 > 98% with a higher slope of the fitted regression line than that below 98% of SpO 2 . Furthermore, receiver‐operating characteristic curve analysis using only SpO 2 ≤ 98% samples showed that the optimal cut‐off points of OSI SpO2 and the S p /F ratio for predicting OI were: OI 5, 3.0 and 332; OI 10, 5.3 and 231; OI 15, 7.7 and 108; OI 20, 11.0 and 149; and OI 25, 17.1 and 103, respectively. Conclusion: The cut‐off OSI SpO2 and S p /F ratio values could allow continuous monitoring for oxygenation changes in neonates with the potential for wider clinical applications.
- 1 January 2024
- Published by Wiley in Pediatrics International
- Vol. 66 (1) , e15753
Oxygenation saturation index in neonatal hypoxemic respiratory failure
Background: This study aimed to assess the validity of the oxygenation saturation index (OSI) and the ratio of oxygen saturation to the fraction of inspired oxygen (F I O 2 ) (S/F ratio) with percutaneous oxygen saturation (OSI SpO2 and the S p /F ratio) and to evaluate the correlation between these values and the oxygen index (OI). It also determined their cut‐off values for predicting OI in accordance with neonatal hypoxic respiratory failure severity. Methods: We reviewed the data of 77 neonates (gestational age 31.7 ± 6.1 weeks; birthweight, 1768 ± 983 g) requiring invasive mechanical ventilation between 2013 and 2020, 1233 arterial blood gas samples in total. We calculated the OI, OSI SpO2 , OSI with arterial oxygen saturation (SaO 2 ) (OSI SaO2 ), S p /F ratio, and the ratio of SaO 2 to F I O 2 (S a /F ratio). Results: The regression and Bland–Altman analysis showed good agreement between OSI SpO2 or the S p /F ratio and OSI SaO2 or the S a /F ratio. Although a significant positive correlation was found between OSI SpO2 and OI, OSI SpO2 was overestimated in SpO 2 > 98% with a higher slope of the fitted regression line than that below 98% of SpO 2 . Furthermore, receiver‐operating characteristic curve analysis using only SpO 2 ≤ 98% samples showed that the optimal cut‐off points of OSI SpO2 and the S p /F ratio for predicting OI were: OI 5, 3.0 and 332; OI 10, 5.3 and 231; OI 15, 7.7 and 108; OI 20, 11.0 and 149; and OI 25, 17.1 and 103, respectively. Conclusion: The cut‐off OSI SpO2 and S p /F ratio values could allow continuous monitoring for oxygenation changes in neonates with the potential for wider clinical applications.
- 25 July 2022
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 29 (12) , 1930-1938
The combination of ruxolitinib and Bcl-2/Mcl-1 inhibitors has a synergistic effect on leukemic cells carrying a SPAG9::JAK2 fusion
JAK2 rearrangements can occur in Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL). Here, we performed functional analysis of the SPAG9::JAK2 fusion, which was identified in a pediatric patient with Ph-like ALL, to establish molecular targeted therapy. Ba/F3 cells expressing SPAG9::JAK2 generated by retroviral transduction (Ba/F3-SPAG9-JAK2), proliferated in the absence of IL-3, and exhibited constitutive phosphorylation of the tyrosine residues in the JAK2 kinase domain of the fusion protein and STAT3/STAT5. Mutation of tyrosine residues in the JAK2 kinase domain (SPAG9::JAK2 mut) abolished IL-3 independence, but had no influence on STAT3/STAT5 phosphorylation levels. Gene expression analysis revealed that Stat1 was significantly upregulated in Ba/F3-SPAG9-JAK2 cells. STAT1 was also phosphorylated in Ba/F3-SPAG9-JAK2 but not SPAG9-JAK2 mut cells, suggesting that STAT1 is key for SPAG9::JAK2-mediated cell proliferation. Consistently, STAT1 induced expression of the anti-apoptotic proteins, BCL-2 and MCL-1, as did SPAG9::JAK2, but not SPAG9::JAK2 mut. Ruxolitinib abrogated Ba/F3-SPAG9-JAK2-mediated proliferation in vitro, but was insufficient in vivo. Venetoclax (a BCL-2 inhibitor) or AZD5991 (an MCL-1 inhibitor) enhanced the effects of ruxolitinib on Ba/F3-SPAG9-JAK2 in vitro. These findings suggest that activation of the JAK2-STAT1-BCL-2/MCL-1 axis contributes to SPAG9::JAK2-related aberrant growth promotion. BCL-2 or MCL-1 inhibition is a potential therapeutic option for B-ALL with SPAG9::JAK2 fusion.
- 25 July 2022
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 29 (12) , 1930-1938
The combination of ruxolitinib and Bcl-2/Mcl-1 inhibitors has a synergistic effect on leukemic cells carrying a SPAG9::JAK2 fusion
JAK2 rearrangements can occur in Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL). Here, we performed functional analysis of the SPAG9::JAK2 fusion, which was identified in a pediatric patient with Ph-like ALL, to establish molecular targeted therapy. Ba/F3 cells expressing SPAG9::JAK2 generated by retroviral transduction (Ba/F3-SPAG9-JAK2), proliferated in the absence of IL-3, and exhibited constitutive phosphorylation of the tyrosine residues in the JAK2 kinase domain of the fusion protein and STAT3/STAT5. Mutation of tyrosine residues in the JAK2 kinase domain (SPAG9::JAK2 mut) abolished IL-3 independence, but had no influence on STAT3/STAT5 phosphorylation levels. Gene expression analysis revealed that Stat1 was significantly upregulated in Ba/F3-SPAG9-JAK2 cells. STAT1 was also phosphorylated in Ba/F3-SPAG9-JAK2 but not SPAG9-JAK2 mut cells, suggesting that STAT1 is key for SPAG9::JAK2-mediated cell proliferation. Consistently, STAT1 induced expression of the anti-apoptotic proteins, BCL-2 and MCL-1, as did SPAG9::JAK2, but not SPAG9::JAK2 mut. Ruxolitinib abrogated Ba/F3-SPAG9-JAK2-mediated proliferation in vitro, but was insufficient in vivo. Venetoclax (a BCL-2 inhibitor) or AZD5991 (an MCL-1 inhibitor) enhanced the effects of ruxolitinib on Ba/F3-SPAG9-JAK2 in vitro. These findings suggest that activation of the JAK2-STAT1-BCL-2/MCL-1 axis contributes to SPAG9::JAK2-related aberrant growth promotion. BCL-2 or MCL-1 inhibition is a potential therapeutic option for B-ALL with SPAG9::JAK2 fusion.
- 21 January 2022
- Published by Wiley in Pediatrics International
- Vol. 64 (1) , e14899
Pediatric subarachnoid hemorrhage and aneurysm caused by fibromuscular dysplasia
- 21 January 2022
- Published by Wiley in Pediatrics International
- Vol. 64 (1) , e14899
Pediatric subarachnoid hemorrhage and aneurysm caused by fibromuscular dysplasia
- 1 January 2022
- Vol. 63 (1) , 45-50
[HLA-mismatched bone marrow transplantation with post-transplant cyclophosphamide for pediatric patients with aplastic anemia].
Post-transplant cyclophosphamide (PTCy) has improved the efficacy of HLA-mismatched hematopoietic cell transplantation (HCT) by decreasing the risk of graft-versus-host disease (GVHD) and nonrelapse mortality. If an HLA-matched donor is not available, GVHD prophylaxis with PTCy can also be used for HLA-mismatched HCT in patients with pediatric aplastic anemia (AA). We report two cases of pediatric AA that were treated with HLA-mismatched HCT with reduced-intensity conditioning and PTCy. We administered 50 mg/kg/day Cy for GVHD prophylaxis on days 3 and 4, and tacrolimus and mycophenolate mofetil (or methotrexate) were initiated from day 5. In both the cases, the time to engraftment was favorable and GVHD and infection were controllable. PTCy probably allows us to expand donor candidates in pediatric AA when an HLA-matched donor is not available; however, further studies regarding optimal conditioning regimens and late complications are required.
- 1 January 2022
- Vol. 63 (1) , 45-50
[HLA-mismatched bone marrow transplantation with post-transplant cyclophosphamide for pediatric patients with aplastic anemia].
Post-transplant cyclophosphamide (PTCy) has improved the efficacy of HLA-mismatched hematopoietic cell transplantation (HCT) by decreasing the risk of graft-versus-host disease (GVHD) and nonrelapse mortality. If an HLA-matched donor is not available, GVHD prophylaxis with PTCy can also be used for HLA-mismatched HCT in patients with pediatric aplastic anemia (AA). We report two cases of pediatric AA that were treated with HLA-mismatched HCT with reduced-intensity conditioning and PTCy. We administered 50 mg/kg/day Cy for GVHD prophylaxis on days 3 and 4, and tacrolimus and mycophenolate mofetil (or methotrexate) were initiated from day 5. In both the cases, the time to engraftment was favorable and GVHD and infection were controllable. PTCy probably allows us to expand donor candidates in pediatric AA when an HLA-matched donor is not available; however, further studies regarding optimal conditioning regimens and late complications are required.
- 1 January 2022
- Published by Wiley in Pediatrics International
- Vol. 64 (1) , e15078
Acute promyelocytic leukemia complicated by iliac subperiosteal hematoma
- 1 January 2022
- Published by Wiley in Pediatrics International
- Vol. 64 (1) , e15078
Acute promyelocytic leukemia complicated by iliac subperiosteal hematoma
- 29 March 2021
- Published by Springer Nature in International Journal of Hematology
- Vol. 113 (5) , 616-617
Relapsed RUNX1-RUNX1T1-positive acute myeloid leukemia with pseudo-Chediak-Higashi granules
- 29 March 2021
- Published by Springer Nature in International Journal of Hematology
- Vol. 113 (5) , 616-617
Relapsed RUNX1-RUNX1T1-positive acute myeloid leukemia with pseudo-Chediak-Higashi granules
- Open Access
- 3 August 2020
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 180 (1) , 241-246
Reduction in minute alveolar ventilation causes hypercapnia in ventilated neonates with respiratory distress
Hypercapnia occurs in ventilated infants even if tidal volume (VT) and minute ventilation (VE) are maintained. We hypothesised that increased physiological dead space (Vd,phys) caused decreased minute alveolar ventilation (VA; alveolar ventilation (VA) × respiratory rate) in well-ventilated infants with hypercapnia. We investigated the relationship between dead space and partial pressure of carbon dioxide (PaCO2) and assessed VA. Intubated infants (n = 33; mean birth weight, 2257 ± 641 g; mean gestational age, 35.0 ± 3.3 weeks) were enrolled. We performed volumetric capnography (Vcap), and calculated Vd,phys and VA when arterial blood sampling was necessary. PaCO2 was positively correlated with alveolar dead space (Vd,alv) (r = 0.54, p < 0.001) and Vd,phys (r = 0.48, p < 0.001), but not Fowler dead space (r = 0.14, p = 0.12). Normocapnia (82 measurements; 35 mmHg ≤ PaCO2 < 45 mmHg) and hypercapnia groups (57 measurements; 45 mmHg ≤ PaCO2) were classified. The hypercapnia group had higher Vd,phys (median 0.57 (IQR, 0.44–0.67)) than the normocapnia group (median Vd,phys/VT = 0.46 (IQR, 0.37–0.58)], with no difference in VT. The hypercapnia group had lower VA (123 (IQR, 87–166) ml/kg/min) than the normocapnia group (151 (IQR, 115–180) ml/kg/min), with no difference in VE. Conclusion: Reduction of VA in well-ventilated neonates induces hypercapnia, caused by an increase in Vd,phys. What is Known: • Volumetric capnography based on ventilator graphics and capnograms is a useful tool in determining physiological dead space of ventilated infants and investigating the cause of hypercapnia. What is New: • This study adds evidence that reduction in minute alveolar ventilation causes hypercapnia in ventilated neonates.
- 3 August 2020
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 180 (1) , 241-246
Open AccessReduction in minute alveolar ventilation causes hypercapnia in ventilated neonates with respiratory distress
Hypercapnia occurs in ventilated infants even if tidal volume (VT) and minute ventilation (VE) are maintained. We hypothesised that increased physiological dead space (Vd,phys) caused decreased minute alveolar ventilation (VA; alveolar ventilation (VA) × respiratory rate) in well-ventilated infants with hypercapnia. We investigated the relationship between dead space and partial pressure of carbon dioxide (PaCO2) and assessed VA. Intubated infants (n = 33; mean birth weight, 2257 ± 641 g; mean gestational age, 35.0 ± 3.3 weeks) were enrolled. We performed volumetric capnography (Vcap), and calculated Vd,phys and VA when arterial blood sampling was necessary. PaCO2 was positively correlated with alveolar dead space (Vd,alv) (r = 0.54, p < 0.001) and Vd,phys (r = 0.48, p < 0.001), but not Fowler dead space (r = 0.14, p = 0.12). Normocapnia (82 measurements; 35 mmHg ≤ PaCO2 < 45 mmHg) and hypercapnia groups (57 measurements; 45 mmHg ≤ PaCO2) were classified. The hypercapnia group had higher Vd,phys (median 0.57 (IQR, 0.44–0.67)) than the normocapnia group (median Vd,phys/VT = 0.46 (IQR, 0.37–0.58)], with no difference in VT. The hypercapnia group had lower VA (123 (IQR, 87–166) ml/kg/min) than the normocapnia group (151 (IQR, 115–180) ml/kg/min), with no difference in VE. Conclusion: Reduction of VA in well-ventilated neonates induces hypercapnia, caused by an increase in Vd,phys. What is Known: • Volumetric capnography based on ventilator graphics and capnograms is a useful tool in determining physiological dead space of ventilated infants and investigating the cause of hypercapnia. What is New: • This study adds evidence that reduction in minute alveolar ventilation causes hypercapnia in ventilated neonates.
- 11 July 2020
- Published by Springer Nature in International Journal of Hematology
- Vol. 112 (5) , 714-719
Functional analysis of a novel fusion protein PAX5-KIDINS220 identified in a pediatric Ph-like ALL patient
PAX5-KIDINS220 (PAX5-K220) is a novel chimeric fusion gene identified in a pediatric Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) patient, but the function of the encoded fusion protein has not yet been analyzed. Here, we report the functional analysis of PAX5-K220 in vitro. We successfully generated PAX5-K220 expressing cells and demonstrate that PAX5-K220 is a nuclear protein. Luciferase reporter assay reveals that PAX5-K220 inhibits wild-type PAX5 transcriptional activity in a dominant-negative fashion like other PAX5-related fusion proteins, and may contribute to lymphocyte differentiation block. However, although identified in Ph-like ALL, PAX5-K220 does not induce IL-3-independent proliferation when transduced in the IL-3-dependent Ba/F3 murine leukemia cells, but rather attenuates growth. These results reveal that PAX5-K220 certainly shares the character with other PAX5-related fusion proteins rather than other fusion proteins with tyrosine kinase activity identified in Ph-like ALL, and did not contribute to proliferation activity. Precise functional analysis of each differently partnered PAX5 fusion protein is warranted in the future for better understanding of PAX5-related translocations and their effects.
- 11 July 2020
- Published by Springer Nature in International Journal of Hematology
- Vol. 112 (5) , 714-719
Functional analysis of a novel fusion protein PAX5-KIDINS220 identified in a pediatric Ph-like ALL patient
PAX5-KIDINS220 (PAX5-K220) is a novel chimeric fusion gene identified in a pediatric Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) patient, but the function of the encoded fusion protein has not yet been analyzed. Here, we report the functional analysis of PAX5-K220 in vitro. We successfully generated PAX5-K220 expressing cells and demonstrate that PAX5-K220 is a nuclear protein. Luciferase reporter assay reveals that PAX5-K220 inhibits wild-type PAX5 transcriptional activity in a dominant-negative fashion like other PAX5-related fusion proteins, and may contribute to lymphocyte differentiation block. However, although identified in Ph-like ALL, PAX5-K220 does not induce IL-3-independent proliferation when transduced in the IL-3-dependent Ba/F3 murine leukemia cells, but rather attenuates growth. These results reveal that PAX5-K220 certainly shares the character with other PAX5-related fusion proteins rather than other fusion proteins with tyrosine kinase activity identified in Ph-like ALL, and did not contribute to proliferation activity. Precise functional analysis of each differently partnered PAX5 fusion protein is warranted in the future for better understanding of PAX5-related translocations and their effects.
- 24 August 2018
- Published by Springer Nature in International Journal of Hematology
- Vol. 108 (6) , 665-669
KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia
Mixed lineage leukemia [MLL; now known as lysine methyltransferase 2A (KMT2A)] rearrangement-positive acute myeloid leukemia (AML) and juvenile myelomonocytic leukemia (JMML) are distinct diseases, although age of susceptibility (infancy or early childhood) and abnormal monocytosis are common clinical features. Here, we report two cases of KMT2A-rearranged infantile AML masquerading as JMML at initial presentation. Both cases showed leukocytosis accompanied by atypical monocytosis. However, in both cases, leukemic blasts were absent at the initial examination. Thus, a diagnosis of JMML was suspected. However, initial cytogenetic analysis revealed that both cases had an 11q23 rearrangement, which is atypical in JMML. Eventually, due to the emergence of leukemic blasts and further cytogenetic studies, both cases were diagnosed with infantile AML with a KMT2A rearrangement. Although one patient remains in complete remission after the completion of AML appropriate chemotherapy, the other died of AML due to treatment failure. Our experience suggests that AML with KMT2A rearrangement should be considered for the differential diagnosis of infantile cases with atypical monocytosis suggestive of JMML. Cytogenetic studies, including fluorescence in situ hybridization analysis of KMT2A, may be helpful in distinguishing between AML with KMT2A rearrangement and JMML.
- 24 August 2018
- Published by Springer Nature in International Journal of Hematology
- Vol. 108 (6) , 665-669
KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia
Mixed lineage leukemia [MLL; now known as lysine methyltransferase 2A (KMT2A)] rearrangement-positive acute myeloid leukemia (AML) and juvenile myelomonocytic leukemia (JMML) are distinct diseases, although age of susceptibility (infancy or early childhood) and abnormal monocytosis are common clinical features. Here, we report two cases of KMT2A-rearranged infantile AML masquerading as JMML at initial presentation. Both cases showed leukocytosis accompanied by atypical monocytosis. However, in both cases, leukemic blasts were absent at the initial examination. Thus, a diagnosis of JMML was suspected. However, initial cytogenetic analysis revealed that both cases had an 11q23 rearrangement, which is atypical in JMML. Eventually, due to the emergence of leukemic blasts and further cytogenetic studies, both cases were diagnosed with infantile AML with a KMT2A rearrangement. Although one patient remains in complete remission after the completion of AML appropriate chemotherapy, the other died of AML due to treatment failure. Our experience suggests that AML with KMT2A rearrangement should be considered for the differential diagnosis of infantile cases with atypical monocytosis suggestive of JMML. Cytogenetic studies, including fluorescence in situ hybridization analysis of KMT2A, may be helpful in distinguishing between AML with KMT2A rearrangement and JMML.
- 26 July 2017
- Published by Wiley in Pediatrics International
- Vol. 59 (7) , 843-845
Pediatric T‐ALL complicated by irreversible nelarabine neurotoxicity
- 26 July 2017
- Published by Wiley in Pediatrics International
- Vol. 59 (7) , 843-845
Pediatric T‐ALL complicated by irreversible nelarabine neurotoxicity